Supply Chain Archives
08/04/2025
ATMP Development in 2025: Promise, Pressure, and the Push to Scale
As the advanced therapy medicinal products (ATMP) sector reaches the midpoint of 2025, there’s no shortage of scientific momentum. Groundbreaking CRISPR-based therapies are making headlines. Patient access to cell and gene therapies is expanding beyond early adopter markets. And a maturing global regulatory environment is slowly but surely creating new opportunities for commercialization. But alongside this promise comes pressure.
03/24/2025
Strengthening Global ATMP Logistics: How Cryoport Systems’ Netherlands Facility Supports Temperature-Controlled Supply Chains
The success of ATMPs depends on more than just scientific breakthroughs, it requires a highly controlled, risk-mitigated supply chain that ensures product integrity from research through commercialization. With cell and gene therapies moving across multiple clinical sites, manufacturing facilities, and regulatory jurisdictions, developers need a logistics partner that can support seamless, temperature-controlled supply chain management at a global scale.
03/21/2025
Strengthening ATMP Development in Europe: How BioServices Centers in France Enable Efficiency and Scalability
As Advanced Therapy Medicinal Product (ATMP) developers progress from early-stage research to late-phase clinical trials and commercialization, biostorage, sample management, and regulatory-compliant logistics become increasingly complex. Efficiently managing these critical components is essential to ensure product integrity, regulatory compliance, and seamless supply chain operations.
03/21/2025
Optimizing ATMP Cryopreservation: How IntegriCell™ Services in Belgium Ensure Cell Viability and Supply Chain Integrity
Cryopreservation is quickly becoming a critical yet often underestimated component of the Advanced Therapy Medicinal Product (ATMP) supply chain. The success of cell-based therapies depends on maintaining cell viability, stability, and consistency, yet variability in cryopreservation methods has compromised therapeutic outcomes.
03/12/2025
Global Experts, Local Presence: Strengthening Europe’s Advanced Therapy Supply Chain
The development and commercialization of Advanced Therapy Medicinal Products (ATMPs) in Europe require a highly coordinated supply chain. From temperature-controlled logistics and biostorage to regulatory compliance, every stage of the ATMP lifecycle depends on precision, reliability, and risk mitigation
03/12/2025
The Gateway to Europe: How Cryoport Systems’ Stevenage Supply Chain Hub Supports ATMP Development
For UK-based Advanced Therapy Medicinal Product (ATMP) developers, access to European clinical trial sites and commercial markets is a critical component of a successful growth strategy. Yet, navigating regulatory barriers, customs challenges, and supply chain complexities can create unnecessary delays, increase costs, and put the integrity of sensitive biologics at risk.
09/24/2024
Celebrating Our Recent Facility Expansion: A Recap of our Stevenage Global Supply Chain Hub Grand Opening Event
We recently had the pleasure of celebrating the official grand opening of our newest Global Supply Chain Hub in Stevenage, UK, alongside local clients and partners.
09/03/2024
